DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance

• Published in: British journal of cancer 2024
• Main Authors: Cyll, Karolina Urszula, Haug, Erik Skaaheim, Pradhan, Manohar, Vlatkovic, Ljijana, Carlsen, Birgitte, Löffeler, Sven, Kildal, Wanja, Skogstad, Karin, Torkelsen, Frida Hauge, Syvertsen, Rolf Anders, Askautrud, Hanne Arenberg, Liestøl, Knut, Kleppe, Andreas, Danielsen, Håvard Emil Greger
• Format: Article
• Language: Norwegian
• ISSN: 0007-0920

Background: Current risk stratification tools for prostate cancer patients under active surveillance (AS) may inadequately identify those needing treatment. We investigated DNA ploidy and PTEN as potential biomarkers to predict aggressive disease in AS patients. Methods: We assessed DNA ploidy by image cytometry and PTEN protein expression by immunohistochemistry in 3197 tumour-containing tissue blocks from 558 patients followed in AS at a Norwegian local hospital. The primary endpoint was treatment, with treatment failure (biochemical recurrence or initiation of salvage therapy) as the secondary endpoint. Results: The combined DNA ploidy and PTEN (DPP) status at diagnosis was associated with treatment-free survival in univariable- and multivariable analysis, with a HR for DPP-aberrant vs. DPP-normal tumours of 2.12 (p < 0.0001) and 1.94 (p < 0.0001), respectively. Integration of DNA ploidy and PTEN status with the Cancer of the Prostate Risk Assessment (CAPRA) score improved risk stratification (c-index difference = 0.025; p = 0.0033). Among the treated patients, those with DPP-aberrant tumours exhibited a significantly higher likelihood of treatment failure (HR 2.01; p = 0.027). Conclusions: DNA ploidy and PTEN could serve as additional biomarkers to identify AS patients at increased risk of developing aggressive disease, enabling earlier intervention for nearly 50% of the patients that will eventually receive treatment with current protocol.